Ophthalmology Department, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.
Can J Ophthalmol. 2013 Apr;48(2):115-20. doi: 10.1016/j.jcjo.2012.12.003.
To compare the effect of subconjunctivally injected bevacizumab, etanercept and the combination of both drugs on experimental corneal neovascularization in rats.
Experimental study.
28 male Wistar-Albino rats.
Right corneas of rats were cauterized by silver nitrate sticks. Rats were divided randomly and equally into 4 groups so that each group contained 7 subjects. Immediately after the cauterization, 0.05 ml normal saline was injected subconjunctivally in group 1 (control group); 0.05 ml (1.25 mg) bevacizumab was injected subconjunctivally in group 2; 0.05 ml (1.25 mg) etanercept was injected subconjunctivally in group 3; 0.05 ml (1.25 mg) bevacizumab and 0.05 ml (1.25 mg) etanercept was injected subconjunctivally in group 4. The rats were euthanized on the 8th day, and digital photographs were obtained before the eyes were enucleated. The area of corneal neovascularization was calculated from digital photographs. Corneal sections were analyzed by histopathologically.
The burn stimulus score was +1 or higher in all eyes. The difference of the neovascularization score between groups was found to be statistically significant (p = 0.001). The area of corneal neovascularization was 79.8% in group 1, 43.2% in group 2, 54.5% in group 3, and 34.8% in group 4. In group 4, corneal neovascularization was inhibited more than in the other groups. Histologic examination showed that the treatment groups had less neovascularization, inflammation, and fibroblast activity than the control group (p< 0.05).
Our study has shown that etanercept does have some antiangiogenic and anti-inflammatory effects in treatment of corneal neovascularization. The combination of bevacizumab and etanercept may be a promising approach in the treatment of corneal neovascularization.
比较玻璃体内注射贝伐单抗、依那西普和两种药物联合应用对大鼠实验性角膜新生血管的作用。
实验研究。
28 只雄性 Wistar 白化大鼠。
用硝酸银棒烧灼大鼠右眼。将大鼠随机均分为 4 组，每组 7 只。烧灼后即刻，第 1 组（对照组）结膜下注射 0.05ml 生理盐水；第 2 组结膜下注射 0.05ml（1.25mg）贝伐单抗；第 3 组结膜下注射 0.05ml（1.25mg）依那西普；第 4 组结膜下注射 0.05ml（1.25mg）贝伐单抗和 0.05ml（1.25mg）依那西普。第 8 天处死大鼠，眼球摘出前拍摄数码照片。从数码照片中计算角膜新生血管面积。组织病理学分析角膜切片。
所有眼睛的烧伤刺激评分均为+1 或更高。各组间新生血管评分的差异具有统计学意义（p = 0.001）。第 1 组角膜新生血管面积为 79.8%，第 2 组为 43.2%，第 3 组为 54.5%，第 4 组为 34.8%。第 4 组角膜新生血管的抑制作用强于其他组。组织学检查显示，与对照组相比，治疗组新生血管、炎症和纤维母细胞活性减少（p<0.05）。
本研究表明，依那西普在治疗角膜新生血管方面确实具有一定的抗血管生成和抗炎作用。贝伐单抗和依那西普联合应用可能是治疗角膜新生血管的一种有前途的方法。
Zotero 插件